Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approach leverages the body’s proteasome system to …